PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

Br J Cancer. 2018 Mar 20;118(6):820-824. doi: 10.1038/bjc.2018.9. Epub 2018 Mar 6.

Authors

Affiliations

¹ Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
² Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
³ General pathology, Department of Translational Research and New Technologies in Surgery and Medicine, University of Pisa, Pisa, Italy.

Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / administration & dosage
Carcinoma, Non-Small-Cell Lung / blood
Carcinoma, Non-Small-Cell Lung / drug therapy
Exosomes / drug effects
Exosomes / genetics*
Exosomes / immunology
Female
Humans
Lung Neoplasms / blood
Lung Neoplasms / drug therapy
Male
Melanoma / blood
Melanoma / drug therapy
Middle Aged
Nivolumab / administration & dosage
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / biosynthesis
Programmed Cell Death 1 Receptor / genetics*
Programmed Cell Death 1 Receptor / immunology
RNA, Messenger / biosynthesis*
RNA, Messenger / blood
RNA, Messenger / genetics

Substances

Antibodies, Monoclonal, Humanized
PDCD1 protein, human
Programmed Cell Death 1 Receptor
RNA, Messenger
Nivolumab
pembrolizumab